denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
Hematology Disease Topics & Pathways:
Biological, antibodies, Diseases, Therapies, Combinations, Adverse Events, DLBCL, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies
Session: Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
Hematology Disease Topics & Pathways:
Biological, antibodies, Diseases, Therapies, Combinations, Adverse Events, DLBCL, B-Cell Lymphoma, immunotherapy, Lymphoid Malignancies
Monday, December 7, 2020, 11:25 AM-11:30 AM
Disclosures: Maddocks: Pharmacyclics: Consultancy, Honoraria; Karyopharm: Consultancy; Seattle Genetics: Consultancy, Honoraria; Morphosys: Consultancy, Honoraria; BMS: Consultancy, Research Funding; Celgene: Consultancy, Honoraria; ADC Therapeutics, AstraZeneca: Consultancy.
OffLabel Disclosure: will include current tafa+len data which is under review for approval
See more of: Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
See more of: Education Program
See more of: Education Program
<< Previous Presentation
|
Next Presentation